LumiThera

11 articles with LumiThera

• LumiThera Announces First Patient Enrollment in the European Multi-Center, LIGHTSITE II Clinical Study to Treat Dry Age-Related Macular Degeneration

  4/11/2019

  LumiThera Inc. announced it has begun enrolling patients in a European Union multi-center clinical study in dry Age-Related Macular Degeneration patients.

• LumiThera Receives Seattle Business Magazine 2019 Leaders in Health Care Award for Achievement in Medical Technology

  3/12/2019

  The Leaders in Health Care Awards is considered to be one of the Pacific Northwest's most distinguished health care awards events of the year.

• LumiThera Announces an Agreement with Andrec Corporation S.A. to Distribute the Valeda Light Delivery System in Colombia and Several Latin American Countries

  3/7/2019

  LumiThera Inc. announced an agreement with Andrec Corporation S.A. to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in Colombia and several Latin America countries.

• LumiThera Receives Notice of Award for $2.5 Million National Eye Institute Grant to Support U.S. Multi-Center Clinical Trial for Treating Dry Age-Related Macular Degeneration

  2/26/2019

  The phase II grant supports a prospective, randomized, multi-center human clinical trial in U.S. subjects diagnosed with dry age-related macular degeneration

• LumiThera Announces a Distribution Agreement for the Valeda Light Delivery System with Miloftalmica in Italy

  12/11/2018

  LumiThera, Inc., announced a distribution agreement with Miloftalmica to exclusively distribute the Valeda™ Light Delivery System for the treatment of dry age-related macular degeneration (AMD) in Italy.

• LumiThera and Optos Announce Collaboration to Commercialize the Valeda™ Light Delivery System for Treating Dry Age-Related Macular Degeneration in Europe

  10/24/2018

  Optos is recognized as the leading provider of ultra-widefield retinal imaging devices to eyecare professionals for improved patient eye care.

• LumiThera, Inc. Selected to Present at the Ophthalmology Innovation Summit 2018 at the American Academy of Ophthalmology, Chicago, IL

  10/19/2018

  LumiThera® Inc., a commercial-stage medical device company focused on developing photobiomodulation (PBM) therapies for ocular disorders and disease, today announced that it will present at the Ophthalmology Innovation Summit at the American Academy of Ophthalmology (OIS@AAO) meeting on October 25, 2018, in Chicago, IL.

• LumiThera LT-300 Device For Treating Dry Advanced Macular Degeneration Granted CE Mark

  6/22/2018

  The "CE" mark is the abbreviation for Conformité Européenne, meaning European Conformity.

• LumiThera Presents LIGHTSITE I Dry AMD Top Line Final Data

  5/1/2018

  LumiThera Inc. presented topline final results from the LIGHTSITE I clinical trial for the treatment of dry age-related macular degeneration (AMD) utilizing its LT-300 Light Delivery System.

• LumiThera Inc. to Present at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS)

  3/13/2018

  LumiThera Inc., a clinical stage medical device company focused on developing non-invasive photobiomodulation (PBM) therapies for ocular disorders and disease, today announces that Clark E. Tedford, Ph.D., Chief Executive Officer, is scheduled to present on Saturday, March 17, 2018 at 9:30 a.m. China Standard Time, at the 2018 Inaugural China Healthcare Investment & Partnering Symposium (CHIPS) in Hangzhou, China.

• LumiThera Unveils LIGHTSITE I Dry AMD Clinical Interim Data

  11/7/2017

  The 30-subject pilot study funded from a SBIR grant awarded to the Company from the NIH and the National Eye Institute is testing each subject's vision and examining disease pathology in the eye, following PBM treatments for up to one year.